FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129337940> ?p ?o ?g. }

• W2129337940 endingPage "E182" @default.
• W2129337940 startingPage "E173" @default.
• W2129337940 abstract "The purpose of the study was to explore optimal combinations of currently actively developed drugs for dually targeting the Ras → Raf → MAPK kinase (MEK) → MAPK/ERK (MAPK) and the phosphatidylinositol 3-kinase/Akt pathways as effective treatments for thyroid cancer. We tested the combinations of the Akt inhibitors MK2206 or perifosine with the BRAFV600E inhibitor PLX4032 or the MEK1/2 inhibitor AZD6244 in thyroid cancer cells harboring both the BRAFV600E and PIK3CA mutations. We found that MK2206 could potently, when used alone, and synergistically, when combined with either PLX4032 or AZD6244, inhibit thyroid cancer cell growth with all the combination index values lower than 1. Perifosine could potently inhibit thyroid cancer cell growth when used alone, but a strong antagonism occurred between this drug and PLX4032 or AZD6244 in the inhibition of thyroid cancer cell growth with all combination index values higher than 1. Combinations of MK2206 with PLX4032 or AZD6244 dramatically enhanced G1 cell cycle arrest induced by each drug alone. However, G2 cell cycle arrest uniquely induced by perifosine alone and G1 cell cycle arrest induced by PLX4032 or AZD6244 were both reversed by combination treatments, providing a mechanism for their antagonism. All these drugs could correspondingly inhibit the MAPK and phosphatidylinositol 3-kinase/Akt signalings, confirming their expected target effects. We demonstrated, unexpectedly, opposite outcomes of MK2206 and perifosine in their combinational treatments with BRAFV600E/MEK inhibitors in thyroid cancer cells. The data may help appropriate selection of these prominent drugs for clinical trials of combination therapies for thyroid cancer." @default.
• W2129337940 created "2016-06-24" @default.
• W2129337940 creator A5039105718 @default.
• W2129337940 creator A5054215561 @default.
• W2129337940 creator A5059437825 @default.
• W2129337940 date "2012-02-01" @default.
• W2129337940 modified "2023-09-23" @default.
• W2129337940 title "The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAF^V600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells" @default.
• W2129337940 cites W1606225900 @default.
• W2129337940 cites W1971947883 @default.
• W2129337940 cites W1973932751 @default.
• W2129337940 cites W1974091059 @default.
• W2129337940 cites W1974701973 @default.
• W2129337940 cites W2001404126 @default.
• W2129337940 cites W2007867839 @default.
• W2129337940 cites W2011360946 @default.
• W2129337940 cites W2011509847 @default.
• W2129337940 cites W2030364029 @default.
• W2129337940 cites W2037574296 @default.
• W2129337940 cites W2041106825 @default.
• W2129337940 cites W2048756258 @default.
• W2129337940 cites W2049179297 @default.
• W2129337940 cites W2064301710 @default.
• W2129337940 cites W2065430948 @default.
• W2129337940 cites W2070563197 @default.
• W2129337940 cites W2082813064 @default.
• W2129337940 cites W2093291977 @default.
• W2129337940 cites W2095180807 @default.
• W2129337940 cites W2099110265 @default.
• W2129337940 cites W2101888941 @default.
• W2129337940 cites W2106543129 @default.
• W2129337940 cites W2106695112 @default.
• W2129337940 cites W2113307985 @default.
• W2129337940 cites W2114621192 @default.
• W2129337940 cites W2119156172 @default.
• W2129337940 cites W2129400742 @default.
• W2129337940 cites W2133354058 @default.
• W2129337940 cites W2144894645 @default.
• W2129337940 cites W2149000868 @default.
• W2129337940 cites W2149360610 @default.
• W2129337940 cites W2155008672 @default.
• W2129337940 cites W2155691517 @default.
• W2129337940 cites W2159750196 @default.
• W2129337940 cites W2166779556 @default.
• W2129337940 cites W2167359586 @default.
• W2129337940 cites W2261566286 @default.
• W2129337940 cites W3080988173 @default.
• W2129337940 cites W2012944210 @default.
• W2129337940 doi "https://doi.org/10.1210/jc.2011-1054" @default.
• W2129337940 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3275354" @default.
• W2129337940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22090271" @default.
• W2129337940 hasPublicationYear "2012" @default.
• W2129337940 type Work @default.
• W2129337940 sameAs 2129337940 @default.
• W2129337940 citedByCount "52" @default.
• W2129337940 countsByYear W21293379402012 @default.
• W2129337940 countsByYear W21293379402013 @default.
• W2129337940 countsByYear W21293379402014 @default.
• W2129337940 countsByYear W21293379402015 @default.
• W2129337940 countsByYear W21293379402016 @default.
• W2129337940 countsByYear W21293379402017 @default.
• W2129337940 countsByYear W21293379402018 @default.
• W2129337940 countsByYear W21293379402019 @default.
• W2129337940 countsByYear W21293379402020 @default.
• W2129337940 countsByYear W21293379402021 @default.
• W2129337940 countsByYear W21293379402022 @default.
• W2129337940 countsByYear W21293379402023 @default.
• W2129337940 crossrefType "journal-article" @default.
• W2129337940 hasAuthorship W2129337940A5039105718 @default.
• W2129337940 hasAuthorship W2129337940A5054215561 @default.
• W2129337940 hasAuthorship W2129337940A5059437825 @default.
• W2129337940 hasBestOaLocation W21293379401 @default.
• W2129337940 hasConcept C121608353 @default.
• W2129337940 hasConcept C126322002 @default.
• W2129337940 hasConcept C184235292 @default.
• W2129337940 hasConcept C185592680 @default.
• W2129337940 hasConcept C2779761222 @default.
• W2129337940 hasConcept C2781249067 @default.
• W2129337940 hasConcept C2781461381 @default.
• W2129337940 hasConcept C502942594 @default.
• W2129337940 hasConcept C55493867 @default.
• W2129337940 hasConcept C57074206 @default.
• W2129337940 hasConcept C62478195 @default.
• W2129337940 hasConcept C71924100 @default.
• W2129337940 hasConcept C75217442 @default.
• W2129337940 hasConcept C86554907 @default.
• W2129337940 hasConcept C98274493 @default.
• W2129337940 hasConceptScore W2129337940C121608353 @default.
• W2129337940 hasConceptScore W2129337940C126322002 @default.
• W2129337940 hasConceptScore W2129337940C184235292 @default.
• W2129337940 hasConceptScore W2129337940C185592680 @default.
• W2129337940 hasConceptScore W2129337940C2779761222 @default.
• W2129337940 hasConceptScore W2129337940C2781249067 @default.
• W2129337940 hasConceptScore W2129337940C2781461381 @default.
• W2129337940 hasConceptScore W2129337940C502942594 @default.
• W2129337940 hasConceptScore W2129337940C55493867 @default.
• W2129337940 hasConceptScore W2129337940C57074206 @default.
• W2129337940 hasConceptScore W2129337940C62478195 @default.

• next